Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
GHD
Interventions
GenSci004, Genotropin
Drug
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Industry
Eligibility
3 Years to 12 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Pituitary Dwarfism, Idiopathic Short Stature
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Jacksonville, Florida
Conditions
Growth Disorder, Growth Hormone Deficiency in Children
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
4 Years to 13 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
24
States / cities
Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions
somapacitan, Norditropin® FlexPro® pen
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
2 Years to 10 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Madera, California + 18 more
Conditions
Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Interventions
Lonapegsomatropin [SKYTROFA®], Somatropin Pen Injector
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
2 Years to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Palo Alto, California • Sacramento, California • Aurora, Colorado + 15 more
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children, Growth Disorder, Idiopathic Short Stature
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 15 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
40
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 34 more
Conditions
Growth Disorder
Interventions
somatropin, rDNA origin, for injection
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
9 Years to 16 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
21
States / cities
Los Angeles, California • Wilmington, Delaware • Washington D.C., District of Columbia + 15 more
Conditions
Pediatric Growth Hormone Deficiency
Interventions
Experimental: VRS-317
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Clovis, California • Los Angeles, California • San Diego, California + 20 more
Conditions
Growth Hormone Deficiency
Interventions
growth hormone (Nutropin)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 17 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Growth Hormone Deficiency (GHD)
Interventions
LUM-201, Matched Placebo (Capsules)
Drug · Other
Lead sponsor
Lumos Pharma
Industry
Eligibility
3 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Madera, California • Orange, California + 27 more
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
1 Year to 18 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Altus Pharmaceuticals
Industry
Eligibility
3 Years to 13 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Little Rock, Arkansas • Orlando, Florida • Springfield, Massachusetts + 7 more
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more
Conditions
Growth Hormone Disorder, Pituitary Dwarfism
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
3 Years to 13 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 23 more
Conditions
Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
Interventions
Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
3 Years to 12 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Conditions
Growth Hormone Deficiency, Septo-Optic Dysplasia, Hypopituitarism
Interventions
Nutropin AQ
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 5 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
Interventions
TransCon hGH
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
6 Months to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more
Conditions
Kidney Failure, Chronic, Growth Hormone Deficiency
Interventions
Nutropin AQ
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
8
States / cities
Loma Linda, California • Los Angeles, California • Stanford, California + 3 more
Conditions
Growth Hormone Deficiency
Interventions
Somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Menlo Park, California
Conditions
Growth Hormone Deficiency (GHD)
Interventions
growth hormone (somatropin)
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
3 Years to 11 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
1 Day to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Sacramento, California
Conditions
Growth Hormone Deficiency (GHD)
Interventions
MOD-4023
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Phase 4 Interventional Results available

Growth Hormone and Endothelial Function in Children

NCT00373386
Conditions
Growth Hormone Deficiency, Panhypopituitarism, Short Stature
Interventions
growth hormone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
8 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Columbus, Ohio